Bristol Myers Squibb invests in Abata Therapeutics
Client(s) Bristol-Myers Squibb Company
Jones Day advised Bristol Myers Squibb in its investment in Abata Therapeutics to support the development of its Treg cell therapy products.
Cases & Deals
Contacts
Practices
Locations
Before sending, please note:
Information on www.jonesday.com is for general use and is not legal advice. The mailing of this email is not intended to create, and receipt of it does not constitute, an attorney-client relationship. Anything that you send to anyone at our Firm will not be confidential or privileged unless we have agreed to represent you. If you send this email, you confirm that you have read and understand this notice.